Guardion Health Sciences to Be Added to the Russell 3000 Index
June 14 2021 - 8:05AM
Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the
“Company”), a clinical nutrition and diagnostics company that
develops clinically supported nutrition, supplements, medical foods
and medical devices, today announced that Guardion is being added
to the Russell 3000 Index. The inclusion of Guardion in the Russell
3000 Index will take place at the conclusion of the 2021 Russell
Indexes’ annual reconstitution, which is expected to be effective
after the U.S. market opens on June 28, 2021, according to a
preliminary list of additions posted on June 4, 2021.
“This is an important recognition for Guardion
and a unique opportunity to expand the awareness in our company,
our product offerings, and our stock.” said Bret Scholtes,
Guardion’s CEO.
Membership in the Russell 3000 Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell Indexes primarily by objective,
market-capitalization rankings, and style attributes.
Russell Indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell’s U.S. Indexes.
Russell Indexes are part of FTSE Russell, a leading global index
provider.
About Guardion Health Sciences,
Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI),
is a clinical nutrition and diagnostics company. Guardion offers a
portfolio of science-based, clinically supported nutrition,
supplements, medical foods and diagnostic products that support
healthcare professionals, their patients, and consumers in
achieving health goals. Guardion’s commercial and developmental
initiatives are supported by equally impressive scientific and
medical advisory boards, led by seasoned business executives and
physicians with many years of experience. Information and risk
factors with respect to Guardion and its business, including its
ability to successfully develop and commercialize its proprietary
products and technologies, may be obtained in the Company’s filings
with the SEC at www.sec.gov.
About FTSE Russell
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of indexes
that measure and benchmark markets and asset classes in more than
70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $17.9 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly-owned by the London Stock
Exchange Group. For more information,
visit www.ftserussel.com.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but are not limited to, the Company’s ability
to raise sufficient financing to implement its business plan, the
integration of a new management team, the integration of one or
more acquisitions and targets, the impact of the COVID-19 pandemic
on the Company’s business, operations and the economy in general,
the Company’s ability to successfully develop and commercialize its
proprietary products and technologies, and the Company’s ability to
maintain compliance with Nasdaq’s listing requirements. Readers are
cautioned not to place undue reliance on these forward-looking
statements, as actual results could differ materially from those
described in the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company’s filings with the SEC, which are available at the SEC’s
website (www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Relations Contact:CORE
IRScott Arnold516-222-2560scotta@coreir.com
Media Relation Contact:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024